COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Protocol No
ECOG-EA5181
Principal Investigator
Jonathan Thompson
Phase
III
Summary
This study is being done to answer the following question: Can we extend your life and/or prevent your tumor from coming back by adding a study drug (MEDI4736 (durvalumab)) during chemotherapy and radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced non-small cell lung cancer. The usual approach is defined as chemotherapy and radiation given together followed by the MEDI4736 (durvalumab) for one year.
Description
Testing the Addition of an Antibody toStandard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients
With Unresectable Stage III Non-Small Cell Lung Cancer
Participating Institutions
Froedtert Hospital
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Status
OPEN TO ACCRUAL
Sub Category